Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features

NCT00637494 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT00637494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00637494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Lead sponsor
Corcept Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2008
Completion date
June 30, 2014
Enrollment
292 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

psychosis, psychotic depression, severe major depression with psychotic features